Canadian Corporate News - Biovail Aware of Second Paragraph IV Certification for Wellbutrin XL.
TORONTO, Nov 19, 2004 (CCNMatthews via COMTEX)
Biovail Corporation (NYSE:BVF) (TSX:BVF) has been advised that GlaxoSmithKline (GSK) has received a Notice of Patent Certification associated with an abbreviated new drug application (ANDA) that has been submitted to the U.S. Food and Drug Administration (FDA) by Abrika Pharmaceuticals LLP of Sunrise, FL, seeking marketing approval for a 150 mg generic formulation of Wellbutrin XL(R) (once-daily bupropion).
Related Results
Biovail Announces Receipt Of An Approvable Letter For Wellbutrin XL.
IMS INSIGHTS Rx SALES SLOWING
Biovail shares crash after motorway accident puts dent in revenues.
Biovail Corporation: FDA Approves Wellbutrin XL; New, Once-Daily Antidepressa…
The Collected Works of Paul Lingel
On November 17, Biovail announced that it received notification that Anchen Pharmaceuticals, Inc. had filed an ANDA for a …
Read the rest of this article with a Free Trial at HighBeam Research.
